Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kronos Bio, Inc.

0.7790
-0.0210-2.62%
Volume:295.00K
Turnover:231.75K
Market Cap:47.50M
PE:-0.54
High:0.8250
Open:0.7800
Low:0.7710
Close:0.8000
Loading ...

BRIEF-Kronos Bio Says Norbert Bischofberger Resigns As President & CEO

Reuters
·
27 Nov 2024

Rpt-Kronos Bio Inc -in Connection With Reduction in Workforce, Co Expects to Incur Charge of Approximately $3.7 Mln

THOMSON REUTERS
·
27 Nov 2024

Rpt-Kronos Bio - Approves 83% Workforce Reduction as Part of a Strategic Resource Allocation and Cost Containment Plan

THOMSON REUTERS
·
27 Nov 2024

BRIEF-Kronos Bio Says Norbert Bischofberger Steps Down As President & CEO

Reuters
·
27 Nov 2024

Kronos Bio Announces CEO Transition and Reduction in Force

THOMSON REUTERS
·
27 Nov 2024

Kronos Bio Inc - Norberg Bischofberger Steps Down as President & CEO

THOMSON REUTERS
·
27 Nov 2024

Press Release: Kronos Bio Announces CEO Transition and Reduction in Force

Dow Jones
·
27 Nov 2024

BRIEF-Kronos Bio Approves 83% Workforce Reduction As Part Of A Strategic Resource Allocation And Cost Containment Plan

Reuters
·
27 Nov 2024

Kronos Bio Restructures Workforce and Leadership

TIPRANKS
·
27 Nov 2024

Kronos Bio Inc - Norberg Bischofberger Resigns as President and CEO

THOMSON REUTERS
·
27 Nov 2024

Kronos Bio Inc -in Connection With Reduction in Workforce, Co Expects to Incur Charge of Approximately $3.7 Mln

THOMSON REUTERS
·
27 Nov 2024

Kronos Bio - Approves 83% Workforce Reduction as Part of a Strategic Resource Allocation and Cost Containment Plan

THOMSON REUTERS
·
27 Nov 2024

Kronos Bio Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
16 Nov 2024

Kronos Bio to present preclinical data from p300 KAT inhibitor program

TIPRANKS
·
15 Nov 2024

Kronos Bio provides update on review of strategic alternatives

TIPRANKS
·
15 Nov 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

GlobeNewswire
·
15 Nov 2024

Piper Sandler Downgrades Kronos Bio to Neutral From Overweight, Adjusts Price Target to $1 From $6

MT Newswires Live
·
14 Nov 2024

TD Cowen Downgrades Kronos Bio to Hold From Buy

MT Newswires Live
·
14 Nov 2024

Kronos Bio Cut to Neutral From Overweight by Piper Sandler

Dow Jones
·
14 Nov 2024

Kronos Bio Cut to Hold From Buy by TD Cowen

Dow Jones
·
14 Nov 2024